Cargando…

GLP-1 Receptor Agonists and Kidney Protection

Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greco, Eulalia Valentina, Russo, Giuseppina, Giandalia, Annalisa, Viazzi, Francesca, Pontremoli, Roberto, De Cosmo, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630923/ https://www.ncbi.nlm.nih.gov/pubmed/31159279 http://dx.doi.org/10.3390/medicina55060233

Ejemplares similares

Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
por: Bonino, Barbara, et al.
Publicado: (2019)

Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
por: Leoncini, Giovanna, et al.
Publicado: (2020)

Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative
por: Lamacchia, Olga, et al.
Publicado: (2018)

Diabetic kidney disease in the elderly: prevalence and clinical correlates
por: Russo, Giuseppina T., et al.
Publicado: (2018)

Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative
por: Piscitelli, Pamela, et al.
Publicado: (2017)

Publisher Correction: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative
por: Piscitelli, Pamela, et al.
Publicado: (2018)

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes
por: Mirijello, Antonio, et al.
Publicado: (2018)

Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function
por: Gentile, Sandro, et al.
Publicado: (2017)

Predictors of chronic kidney disease in type 2 diabetes: A longitudinal study from the AMD Annals initiative
por: De Cosmo, Salvatore, et al.
Publicado: (2016)

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus
por: Viazzi, Francesca, et al.
Publicado: (2017)

Metabolic syndrome, serum uric acid and renal risk in patients with T2D
por: Viazzi, Francesca, et al.
Publicado: (2017)

Global Cardiovascular Risk Assessment in the Management of Primary Hypertension: The Role of the Kidney
por: Viazzi, Francesca, et al.
Publicado: (2013)

Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system
por: Viazzi, Francesca, et al.
Publicado: (2013)

Chronic kidney disease as a predictor of clinical risk in the elderly
por: Viazzi, Francesca, et al.
Publicado: (2016)

Erratum. Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. Diabetes Care 2019;42:514–519
por: Ceriello, Antonio, et al.
Publicado: (2020)

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
por: Leoncini, Giovanna, et al.
Publicado: (2021)

Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions
por: Gentile, Sandro, et al.
Publicado: (2018)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components
por: Russo, Elisa, et al.
Publicado: (2023)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
por: Rojano Toimil, Alba, et al.
Publicado: (2021)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
por: Yu, Ji Hee, et al.
Publicado: (2022)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age
por: Russo, Elisa, et al.
Publicado: (2020)

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Influence of peroxisome proliferator-activated receptor-γ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern mediterranean women with polycystic ovary syndrome
por: Giandalia, Annalisa, et al.
Publicado: (2018)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
por: Vandemark, Collin, et al.
Publicado: (2023)

Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors
por: Giandalia, Annalisa, et al.
Publicado: (2021)

Treating Hyperuricemia: The Last Word Hasn’t Been Said Yet
por: Russo, Elisa, et al.
Publicado: (2021)

Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats
por: El Amin Ali, Amani M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fck6hmlhtk26mhpvipdp41qvh0